Acellular Amniotic Fluid Therapy for Ischemic Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic injuries, such as myocardial infarction, are inadequate and often invasive, with limited efficacy due to diverse molecular and cellular pathogenesis, and there is a need for more effective therapeutics.
Innovation Solution
Administering a therapeutically effective amount of acellular amniotic fluid (acAF) to the ischemic injury site within a therapeutic time window, which can include active agents and be delivered via various methods, including intravenous or direct injections, to treat organs like the heart, brain, and limbs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If invasive procedures such as PCI or coronary artery bypass surgery are used to treat ischemic heart failure, then patient survival is extended, but the treatment becomes traumatic with numerous drawbacks and undesirable side effects
Solution Approach 1:
The patent uses acellular amniotic fluid as an intermediary substance that mediates the therapeutic effect between administration and heart tissue repair. This fluid contains growth factors and anti-inflammatory agents that facilitate healing without requiring direct surgical intervention or catheter-based procedures, thereby avoiding the traumatic effects of invasive treatments while maintaining therapeutic efficacy
Solution Approach 2:
The patent replaces mechanical invasive procedures (surgical bypass or percutaneous intervention) with a biochemical treatment approach. Instead of physically opening arteries or creating new blood flow pathways through mechanical means, the treatment uses administered substances that promote endogenous repair mechanisms, substituting mechanical intervention with molecular-level therapeutic action
2Device complexity
If single targeted therapy is used to treat ischemic heart injury, then the treatment pathway is simplified, but efficacy is limited due to diverse feedback systems and resistance to therapy
Solution Approach 1:
The acellular amniotic fluid formulation serves multiple therapeutic functions simultaneously: it provides anti-inflammatory effects, delivers growth factors for tissue repair, modulates immune responses, and promotes angiogenesis. This multi-functional approach addresses the diverse pathophysiological mechanisms of ischemic heart failure through a single comprehensive treatment rather than requiring multiple separate targeted therapies
Solution Approach 2:
The patent employs a composite therapeutic formulation consisting of acellular amniotic fluid containing multiple bioactive components including growth factors, cytokines, and anti-inflammatory agents. This composite material works synergistically to address multiple aspects of heart injury repair simultaneously, overcoming the limitations of single-agent therapies while maintaining a relatively simple administration protocol
Data Source
AI summary
Described herein are compositions and methods for treating ischemic injury in a subject comprising administering a therapeutically effective amount of an acellular amniotic fluid (acAF) to an ischemic injury situs within a therapeutic time window.